Cargando…
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964291/ https://www.ncbi.nlm.nih.gov/pubmed/21049063 http://dx.doi.org/10.1371/journal.pntd.0000855 |
_version_ | 1782189348799643648 |
---|---|
author | Musa, Ahmed M. Younis, Brima Fadlalla, Ahmed Royce, Catherine Balasegaram, Manica Wasunna, Monique Hailu, Asrat Edwards, Tansy Omollo, Raymond Mudawi, Mahmoud Kokwaro, Gilbert El-Hassan, Ahmed Khalil, Eltahir |
author_facet | Musa, Ahmed M. Younis, Brima Fadlalla, Ahmed Royce, Catherine Balasegaram, Manica Wasunna, Monique Hailu, Asrat Edwards, Tansy Omollo, Raymond Mudawi, Mahmoud Kokwaro, Gilbert El-Hassan, Ahmed Khalil, Eltahir |
author_sort | Musa, Ahmed M. |
collection | PubMed |
description | BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days. METHODS: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg. FINDINGS: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively). CONCLUSION: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00255567 |
format | Text |
id | pubmed-2964291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29642912010-11-03 Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study Musa, Ahmed M. Younis, Brima Fadlalla, Ahmed Royce, Catherine Balasegaram, Manica Wasunna, Monique Hailu, Asrat Edwards, Tansy Omollo, Raymond Mudawi, Mahmoud Kokwaro, Gilbert El-Hassan, Ahmed Khalil, Eltahir PLoS Negl Trop Dis Research Article BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days. METHODS: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg. FINDINGS: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively). CONCLUSION: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00255567 Public Library of Science 2010-10-26 /pmc/articles/PMC2964291/ /pubmed/21049063 http://dx.doi.org/10.1371/journal.pntd.0000855 Text en Musa et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Musa, Ahmed M. Younis, Brima Fadlalla, Ahmed Royce, Catherine Balasegaram, Manica Wasunna, Monique Hailu, Asrat Edwards, Tansy Omollo, Raymond Mudawi, Mahmoud Kokwaro, Gilbert El-Hassan, Ahmed Khalil, Eltahir Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title | Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title_full | Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title_fullStr | Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title_full_unstemmed | Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title_short | Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study |
title_sort | paromomycin for the treatment of visceral leishmaniasis in sudan: a randomized, open-label, dose-finding study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964291/ https://www.ncbi.nlm.nih.gov/pubmed/21049063 http://dx.doi.org/10.1371/journal.pntd.0000855 |
work_keys_str_mv | AT musaahmedm paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT younisbrima paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT fadlallaahmed paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT roycecatherine paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT balasegarammanica paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT wasunnamonique paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT hailuasrat paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT edwardstansy paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT omolloraymond paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT mudawimahmoud paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT kokwarogilbert paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT elhassanahmed paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy AT khalileltahir paromomycinforthetreatmentofvisceralleishmaniasisinsudanarandomizedopenlabeldosefindingstudy |